Adiuvo Investments S.A. (ADV.WA)
PLN 0.36
(2.0%)
PLN 0.36
(2.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -5.08 Million PLN | 89.64% |
| 2022 | -42.71 Million PLN | -61451.25% |
| 2021 | -14.52 Million PLN | 101.03% |
| 2020 | -12.88 Million PLN | 23.18% |
| 2019 | -14.75 Million PLN | 56.69% |
| 2018 | -23.42 Million PLN | 18.57% |
| 2017 | -52.51 Million PLN | -39.97% |
| 2016 | -18.44 Million PLN | -10.23% |
| 2015 | -17.28 Million PLN | -49.94% |
| 2014 | -11.52 Million PLN | -357.92% |
| 2013 | -2.71 Million PLN | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.63 Million PLN | 355.87% |
| 2024 Q1 | -2.43 Million PLN | -0.76% |
| 2023 Q3 | -1.11 Million PLN | 41.67% |
| 2023 Q4 | -1.45 Million PLN | -30.26% |
| 2023 FY | - PLN | 89.64% |
| 2023 Q1 | -404 Thousand PLN | 98.96% |
| 2023 Q2 | -1.91 Million PLN | -374.01% |
| 2022 Q2 | -3.23 Million PLN | -452.14% |
| 2022 Q4 | -38.91 Million PLN | -596.53% |
| 2022 Q3 | -5.58 Million PLN | -72.97% |
| 2022 Q1 | -585 Thousand PLN | -113.11% |
| 2022 FY | - PLN | -61451.25% |
| 2021 FY | - PLN | 101.03% |
| 2021 Q3 | -1.55 Million PLN | 1.96% |
| 2021 Q4 | 4.46 Million PLN | 387.38% |
| 2021 Q1 | -316 Thousand PLN | -127.53% |
| 2021 Q2 | -1.58 Million PLN | -401.27% |
| 2020 Q2 | -2.95 Million PLN | -184.04% |
| 2020 Q3 | -1.93 Million PLN | 34.36% |
| 2020 FY | - PLN | 23.18% |
| 2020 Q1 | -1.04 Million PLN | -185.71% |
| 2020 Q4 | 1.14 Million PLN | 159.21% |
| 2019 Q1 | -2.49 Million PLN | 61.07% |
| 2019 FY | - PLN | 56.69% |
| 2019 Q4 | -364 Thousand PLN | 80.58% |
| 2019 Q3 | -1.87 Million PLN | 75.17% |
| 2019 Q2 | -7.54 Million PLN | -202.85% |
| 2018 Q4 | -6.4 Million PLN | -18.36% |
| 2018 FY | - PLN | 18.57% |
| 2018 Q2 | -6.33 Million PLN | 6.61% |
| 2018 Q1 | -6.78 Million PLN | 31.58% |
| 2018 Q3 | -5.4 Million PLN | 14.62% |
| 2017 Q4 | -9.91 Million PLN | -62.14% |
| 2017 Q1 | -4.91 Million PLN | 27.26% |
| 2017 FY | - PLN | -39.97% |
| 2017 Q3 | -6.11 Million PLN | 1.89% |
| 2017 Q2 | -6.23 Million PLN | -26.92% |
| 2016 Q2 | -5.68 Million PLN | -62.32% |
| 2016 Q4 | -6.75 Million PLN | -50.1% |
| 2016 FY | - PLN | -10.23% |
| 2016 Q3 | -4.49 Million PLN | 20.91% |
| 2016 Q1 | -3.5 Million PLN | 44.25% |
| 2015 Q4 | -6.28 Million PLN | -85.28% |
| 2015 Q3 | -3.39 Million PLN | -11.99% |
| 2015 FY | - PLN | -49.94% |
| 2015 Q2 | -3.02 Million PLN | 2.7% |
| 2015 Q1 | -3.11 Million PLN | 81.41% |
| 2014 Q1 | -278 Thousand PLN | -44.79% |
| 2014 Q2 | -2.19 Million PLN | -689.57% |
| 2014 Q3 | -3.69 Million PLN | -68.34% |
| 2014 Q4 | -16.73 Million PLN | -352.94% |
| 2014 FY | - PLN | -357.92% |
| 2013 FY | - PLN | 0.0% |
| 2013 Q4 | -192 Thousand PLN | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Genomtec S.A. | -7.75 Million PLN | 34.438% |
| Medinice S.A. | -4.72 Million PLN | -7.574% |
| Medicalgorithmics S.A. | 2.23 Million PLN | 327.517% |
| Synektik Spólka Akcyjna | 125.43 Million PLN | 104.054% |